Abiomed Stock Hits High On Heart Pump Approval
Medical device maker Abiomed (ABMD) vaulted to a new high of 73.47 Tuesday morning after it announced late Monday that the FDA had approved its heart pump Impella 2.5. The decision was actually a re-approval of sorts. The FDA had first approved Impella in 2008, but in 2013 it reclassified the product as a class III device. The FDA’s website says that class III items “are generally the highest risk devices and are therefore subject to the highest